• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Strattera (atomoxetine hydrochloride) capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – March 2011

 

Summary View

 

CONTRAINDICATIONS

Pheochromocytoma
  • Serious reactions, including elevated blood pressure and tachyarrhythmia, have  been reported in patients with pheochromocytoma or a history of pheochromocytoma who received STRATTERA. Therefore, STRATTERA should not be taken by patients with pheochromocytoma or a history of pheochromocytoma.

Medication Guide

  • addition of similar statement regarding pheochromocytoma